Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Teva Posts $590m Negative EBITDA Amid Opioid Deal And Write-Offs
Russian Invasion Of Ukraine Causes Massive Goodwill Impairment
Jul 28 2022
•
By
Dean Rudge
Teva is looking to return to growth • Source: Christian Horz / Alamy Stock Photo
More from Earnings
More from Business